tbuckley/cabot-search huggingface dataset:
Aortic pulse wave velocity, elasticity, and composition in a nonhuman primate model of atherosclerosis.
Authors: D J Farrar, H D Green, M G Bond, W D Wagner, R A Gobbeé
Journal: Circulation Research (1978)

Aortic pulse wave velocity was determined in Macaca fascicularis monkeys fed either atherogenic or control diets for 36 months. The foot-to-foot velocity and apparent phase velocities of the second through seventh Fourier harmonics at a given diastolic pressure in the atherosclerotic monkeys were 1.5 to 2.0 times the values for the control animals. More than 80% of the aortic intimal surface of the atherosclerotic monkeys was covered with fibrous or fatty plaque, which approximately doubled wall thickness and wall thickness to radius ratio. Angiochemical evaluations showed no difference in collagen or elastin concentration (as a fraction of lipid and mineral-free dried aorta), but the atherosclerotic aortas were 1.5 to 2.0 times that of control in collagen and elastin content (defined as the absolute quantity beneath a square centimeter of intimal surface). Total cholesterol and calcium concentrations in the atherosclerotic aortas were more than 10 times the values for the control aortas. The static circumferential distensibility of the excised atherosclerotic aortas was significantly less than control, but there was no difference in incremental (Young's) modulus of elasticity. The in vitro pressure-strain elastic modulus of the atherosclerotic aortas was more than twice that of control, which was predicted from the enhanced wave velocity. The significantly increased stiffness of the atherosclerotic arteries appeared to be due mainly to the increased wall thickness caused by the atherosclerotic plaques rather than to material changes described by Young's modulus. Extensive medial damage, however, also was present and could have had a major influence on stiffness. Atherosclerosis therefore can result in increased aortic stiffening, detectable by pulse wave velocity, even if there is no change in the overall Young's modulus of elasticity.
Experts Debate Guidelines for Release of Research Information
Authors: C. K. Wittenberg
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Experts Debate Guidelines for Release of Research Information Get access Clarissa K. Wittenberg Clarissa K. Wittenberg Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 5, 7 March 1990, Pages 346–348, https://doi.org/10.1093/jnci/82.5.346 Published: 07 March 1990
Unipolar Bronchial Electrocardiographic Exploration of the Heart in Man
Authors: ISAC GOLDSTEIN, LEON PORDY, KENNETH CHESKY, HAROLD S. ARAI, EUGENE R. SNYDER, SIDNEY FEUERSTEIN
Journal: Circulation (1951)

The method for exploring cardiac potentials through the bronchial tree is described in detail. It consists of obtaining unipolar bronchial leads by inserting a thin No. 4 French catheter into the secondary branches of the bronchial tree as near as possible to the surface of the heart. By this method, electrocardiograms can be obtained on the right side which resemble right auricular endocardiograms. On the left side, left ventricular epicardial and cavity potentials are recorded and these are similar to direct left ventricular surface leads, left intraventricular cavity potentials and esophageal leads at the same level. No arrhythmias or serious reactions occurred during or after this procedure. Preliminary findings in 8 cases are discussed in detail.
1017-161 Measurement of myocardial blood volume and flow velocity in capillaries and arterioles in the myocardium by myocardial contrast echocardiography: Dependency on its measurement unit of backscatter
Authors: Takashi Uehara, Makiko Kita, Takashiro Hirano, Tomoko Fujihara, Kasumi Masuda, Ayako Miki, Kentaro Otani, Toshihiko Asanuma, Fuminobu Ishikura, Shintaro Beppu
Journal: Journal of the American College of Cardiology (2004)
Reply to N. Magné et al
Authors: Michele Y. Halyard, Thomas M. Pisansky, Amylou C. Dueck, Vera J. Suman, Lori J. Pierce, Lawrence J. Solin, Lawrence B. Marks, Nancy Davidson, Silvana Martino, Peter Kaufman, Leila Kutteh, Shaker Dakhil, Edith A. Perez
Journal: Journal of Clinical Oncology (2009)

We thank Magne et al for their thoughtful comments. The issue of cardiac toxicity from trastuzumab used in combination with radiation therapy (RT) for breast cancer remains an important one as women continue to be treated with both of these modalities. We emphasized in our work the need for longer follow-up in these patients treated with both trastuzumab and RT to determine whether our findings of lack of increased cardiac toxicity remain true over a greater length of time. Often cardiac manifestations of RT may not manifest until a decade or more after therapy. We performed two analyses to date evaluating cardiac toxicity acutely up to 14 months after commencement of RT, including the current analysis with a median follow-up of 3.7 years. Future analysis of is planned in the future given the known possibility of late occurrences of cardiac toxicity from RT in breast cancer treatment. Long-term monitoring of ejection fraction and of clinical events for at least 10 additional years from study entry is planned. We agree that great attention must be given to RT planning parameters relative to all critical normal structures that pose a risk for adverse events. In our trial, RT treatment planning details were not collected. Therefore, we are unable to comment on the cardiac volume irradiated in these patients. When our study was developed more than a decade ago, some RT techniques for internal mammary irradiation were known to be associated with greater coincident irradiation of the heart and with cardiac mortality. We were in uncharted territory at that time, so our approach was to prohibit irradiation of the internal mammary nodes in order to minimize the volume of heart irradiated as a safety precaution. More recently, some studies do suggest that patients treated in the older RT era experienced excess cardiac morbidity compared with those treated with more modern techniques where the irradiated cardiac volume is reduced. The use of more modern radiation treatment planning techniques, including three-dimensional computed tomography– based tools, has aided in cardiac sparing in breast cancer therapy. However, additional assessment of these more modern RT techniques, including those used in combination with newer systemic chemotherapeutic agents, is needed to assess the incidence of long-term development of cardiac issues. Despite the lack of longer-term information, we maintain that our recent study provides some assurance that the concurrent administration of RT and trastuzumab is associated with a safety profile that supports its use in contemporary practice. It is imperative that long-term analysis is conducted, and we, indeed, value the need for additional follow-up.
Bone as a Structural Material
Authors: Elizabeth A. Zimmermann, Robert O. Ritchie
Journal: Advanced Healthcare Materials (2015)

As one of the most important natural materials, cortical bone is a composite material comprising assemblies of tropocollagen molecules and nanoscale hydroxyapatite mineral crystals, forming an extremely tough, yet lightweight, adaptive and multi‐functional material. Bone has evolved to provide structural support to organisms, and therefore its mechanical properties are vital physiologically. Like many mineralized tissues, bone can resist deformation and fracture from the nature of its hierarchical structure, which spans molecular to macroscopic length‐scales. In fact, bone derives its fracture resistance with a multitude of deformation and toughening mechanisms that are active at most of these dimensions. It is shown that bone's strength and ductility originate primarily at the scale of the nano to submicrometer structure of its mineralized collagen fibrils and fibers, whereas bone toughness is additionally generated at much larger, micro‐ to near‐millimeter, scales from crack‐tip shielding associated with interactions between the crack path and the microstructure. It is further shown how the effectiveness with which bone's structural features can resist fracture at small to large length‐scales can become degraded by biological factors such as aging and disease, which affect such features as the collagen cross‐linking environment, the homogeneity of mineralization, and the density of the osteonal structures.
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
Authors: J L Anderson, E M Gilbert, B L Alpert, R W Henthorn, A L Waldo, A K Bhandari, R W Hawkinson, E L Pritchett
Journal: Circulation (1989)

Paroxysmal atrial fibrillation (PAF) is a problematic clinical arrhythmia that is usually symptomatic. Unfortunately, few adequate trials and trial methods are available for assessment of the value of therapy, and traditional treatment has often been ineffective or associated with unacceptable side effects. Transtelephonic monitoring is a new method that allows evaluation of paroxysmal arrhythmias and arrhythmia-related symptoms in outpatients. We used a patient-initiated transtelephonic monitor system to evaluate the potential of flecainide, a class 1C antiarrhythmic, in prevention of symptomatic recurrences of PAF. Sixty-four patients qualified for the study (two or more PAF attacks documented within a 4-week baseline period) and entered a dose-finding phase to determine drug tolerance. Dose was incremented at weekly intervals from 200-300 and finally to 400 mg/day. The largest dose that was well tolerated was selected for the 4-month, double-blind, randomized, crossover comparison with placebo. Fifty-five patients entered and 53 received both treatments in the double-blind phase; 48 of these patients without protocol violations were evaluable for efficacy comparisons. Evaluable patients had undergone an average of 3.8 previous drug trials (range, 1-8); 30 were men, 18 had hypertension, and 14 had ischemic heart disease. The study demonstrated a highly significant correlation (p less than 0.0001) between perceived symptoms and documented PAF by transtelephonic monitoring. The rate of symptoms and PAF attacks was also significantly reduced by therapy (median dose, 300 mg/day). The first PAF attack occurred after a median of 3 days on placebo versus 14.5 days on flecainide (p less than 0.001) therapy. Similarly, the time interval between attacks was lengthened, from a median of 6.2 days on placebo to 27.0 days on flecainide (p less than 0.001) therapy. PAF was prevented in 15 patients (31%) during flecainide and four (9%) during placebo therapy (p = 0.013). However, during the study, 13 patients dropped out, seven because of adverse effects (five cardiac), five for other reasons, and one because of cardiac arrest/death. Adverse cardiac events occurred in a total of seven patients (11%) during flecainide therapy. Thus, transtelephonic monitoring is a useful method for documentation of the occurrence of paroxysmal arrhythmias such as PAF and its related symptoms during daily living and for assessment of new therapies in an outpatient setting.
Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement
Authors: Àngel Argilés, Alain Ficheux, Marie Thomas, Jean Yves Bosc, Peter G. Kerr, Ronan Lorho, Jean Louis Flavier, Franck Stec, Christian Adelé, Martine Leblanc, Laurie J. Garred, Bernard Canaud, Henri Mion, Charles M. Mion
Journal: Kidney International (1997)
Storing Guns Safely in Homes With Children and Adolescents
Authors: Thomas B. Cole, Reneé M. Johnson
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1.
Authors: J H Vaughan, J R Valbracht, M D Nguyen, H H Handley, R S Smith, K Patrick, G H Rhodes
Journal: Journal of Clinical Investigation (1995)

In previous studies of infectious mononucleosis, we found IgM autoantibodies which react with hematopoietic cell antigens. Many of these were inhibited by synthetic glycine/alanine peptides representing the glycine/alanine repeat of Epstein-Barr virus nuclear antigen-1. We have cloned and expressed fragments of genes encoding two of these autoantigens. One gene (p542) encodes a protein containing a glycine-rich 28-mer, which is its chief autoantigenic epitope and which represents a newly identified class of evolutionarily conserved autoepitopes. The other gene (p554) encodes a protein that is not demonstrably cross-reactive with Epstein-Barr virus nuclear antigen-1 or with any other EBV protein, but forms complexes with other proteins. Immunoaffinity-purified anti-p542 and anti-p554 have relatively high binding affinities, as evidenced by inhibition at 10(6)-10(8) M-1, and neither autoantibody showed polyreactivity with other common antigens. The data thus suggest that neither autoantibody is simply an expression of polyclonal B cell activation. We conclude that the two autoantigens stimulate autoantibody synthesis by different mechanisms. One autoantigen shares homology to a viral protein which generates cross-reacting antibodies to the autoantigenic epitope. The other has no recognizable cross-reaction with the infecting pathogen and may become immunogenic through complexing with other proteins.
Chronic relapsing thrombotic thrombocytopenic purpura: Role of therapy with cyclosporine
Authors: Donald Pasquale, Rakesh Vidhya, Karen DaSilva, Min-Fu Tsan, Lawrence Lansing, G. Chikkappa
Journal: American Journal of Hematology (1998)

Relapsing thrombotic thrombocytopenic purpura (TTP) is a rare disorder with most individuals experiencing 1 to 5 relapses. We report a patient with 18 episodes of thrombotic thrombocytopenic purpura (TTP), the highest number of relapses thus far described. The last 11 episodes were treated with regimens containing cyclosporine. The patient's medical record was reviewed for pertinent clinical, laboratory, and treatment data. We summarized various parameters for each episode and compared characteristics of relapses treated with vs. without cyclosporine. The initial episode of TTP was unusual in that it failed to respond to plasmapheresis, glucocorticoids, and fresh frozen plasma (FFP). It remitted only following splenectomy. Episodes 2–7 responded to FFP plus prednisone. Episode 8 failed to respond to prednisone plus FFP but remitted promptly with cyclosporine plus prednisone. Subsequently, 2 relapses responded to cyclosporine alone, 2 to cyclosporine plus FFP, 4 to cyclosporine plus prednisone ± FFP, and 2 to cyclosporine, FFP, prednisone, and plasma exchange. There was no difference in remission duration, or in severity or duration of relapses treated with vs. without cyclosporine. Use of cyclosporine, however, significantly decreased the requirement for prednisone and the length of maintenance therapy; thus it is effective mainly as an adjunctive therapy for TTP. Am. J. Hematol. 57:57–61, 1998. Published 1998 Wiley-Liss, Inc.1 This article is a U.S. Government work and, as such, is in the public domain in the United States of America.
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase
Authors: Viktor A. Bokisch, Hans J. Müller-Eberhard
Journal: Journal of Clinical Investigation (1970)

The failure of human serum to give rise to anaphylatoxin activity could be attributed to the presence of a potent inactivator of anaphylatoxin in human serum. The inactivator was isolated and characterized as an alpha-globulin with a molecular weight of approximately 310,000. It was found to abolish the activity of both anaphylatoxins, which are derived respectively from the third and the fifth component of complement, and of bradykinin. Inactivation of C3-derived anaphylatoxin and of bradykinin was accompanied by release of C-terminal arginine from these peptides. The anaphylatoxin inactivator was shown to hydrolyze the synthetic substrates hippuryl-L-arginine and hippuryl-L-lysine and to be inhibited by ethylenediaminetetraacetate (EDTA) or phenanthroline. These observations indicate that the anaphylatoxin inactivator constitutes a metal-dependent enzyme resembling in specificity pancreatic carboxypeptidase B.
Hospitalisation rates explain differences in Medicaid costs across US
Authors: B. Roehr
Journal: BMJ (2011)

The rates and costs of hospitalisation explain much of the difference in states’ spending on beneficiaries of Medicaid, the US joint federal and state health insurance programmes for people on low incomes, a new study concludes. 

Secondary factors were regional differences in the cost of living and of healthcare and the age and mix of patients, the study found ( Health Affairs 2011;30:1316-24, doi:10.1377/hlthaff.2011.0106).

Average annual spending per Medicaid beneficiary across the US was $5163 (£3210; €3610) during the study period, 2001 to 2005. The 10 highest spending states averaged $1650 above that figure, while the 10 lowest spending averaged $1161 below it.

The mid-Atlantic region (New York, New Jersey, and …
TCT-491 Incidence And Predictors Of 30 Days Mortality In Elderly Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Angioplasty
Authors: Antonio Alejandro Castro, Víctor Alfonso Díaz, Franklin Pantaleon, Iván Tomás Blázquez, Guillermo Fernández, Alberto Sáez, José Antonio Alonso, Josue Bustillos, Jorge Sepúlveda, Andrés Romo
Journal: Journal of the American College of Cardiology (2012)
Health Principles and Practice
Authors: Clair Van Norman Langton, C. L. Anderson
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Time and Concentration Components of Indicator-Dilution Curves Recorded Following Central Injections of Dye in Normal Human Subjects
Authors: STEFAN A. CARTER, H. J. C. SWAN, EARL H. WOOD
Journal: Circulation (1959)

Indicator-dilution curves were recorded by oximeters at the ears and the right radial artery following the injection of Evans blue (T 1824) into the superior vena cava and pulmonary arteries of 37 subjects who had no evidence of cardiovascular disease. The variability and ranges of various time and concentration components of these dilution curves are presented. These values can be used as standards of reference in the interpretation of abnormal dilution curves. Some of the factors responsible for the variability of these values in healthy subjects are assessed and discussed.
THE LOCALIZATION AND EXTRACTION OF INTRA-OCULAR FOREIGN BODIES
Authors: JAMES M. PATTON
Journal: JAMA (1922)

That the last word on localization and removal of intra-ocular foreign bodies has not been written is very evident from the diversity of opinion expressed by men who, from a wealth of experience and maturity of judgment, may well be classed as authorities. For example, there is a marked diversity of opinion as to the value and method of localization, a number of men of national influence insisting on a thoroughly accurate localization. Others of equal prominence are satisfied with a lateral and anteroposterior plate, a plate taken with the globe in motion or with two positions of the globe on the same plate. One of our best known operators (McReynolds<sup>1</sup>) does not hesitate to insert the tip of the magnet into the vitreous, to the foreign body if necessary, if it cannot be secured otherwise, while another (Allport<sup>2</sup>) of wide experience cautions us against such a procedure,
Randomized Clinical Trials — Removing Unnecessary Obstacles
Authors: Christina Reith, Martin Landray, P.J. Devereaux, Jackie Bosch, Christopher B. Granger, Colin Baigent, Robert M. Califf, Rory Collins, Salim Yusuf
Journal: New England Journal of Medicine (2013)

The authors, who are experienced clinical trialists, propose a framework for expediting the conduct of clinical trials and reducing what they perceive as unnecessary bureaucracy in current trial regulations.